RxDoctor Payments Data

David Heiser, MD

Urology · Canton, OHNPI 1750380861

Payments from drug & device makers

$4,651in general payments, 2019–2025

Across 246 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Astellas Pharma US Inc$882
  • Endo Pharmaceuticals Inc.$279
  • Neotract Inc.$175
  • Bayer$174
  • Myovant Sciences Inc.$171
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$4,43295%
  • Education$2195%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,651 in reported general payments places this provider in the 60th percentile of 485 urology providers in Ohio.

See all urology providers in Ohio

Medicare billing

Part B allowed, 2024
$111,666
Medicare patients
437
Services billed
982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron15$14,306
Tamsulosin Hcl540$4,414
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst103$2,269
Oxybutynin Chloride ErOxybutynin Chloride171$1,962
Trospium Chloride61$1,826
CefuroximeCefuroxime Axetil128$1,461
Tolterodine Tartrate ErTolterodine Tartrate31$1,337
Finasteride94$1,134
Cefdinir84$964
Levofloxacin234$527
Doxazosin Mesylate60$484
Bicalutamide16$336
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim78$267
Alfuzosin Hcl ErAlfuzosin Hcl20$265
Ciprofloxacin Hcl35$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$882$14,30615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 485 urology providers in Ohio.

Other urology in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →